Overall these results and our previous data firmly establishes GSDMB as a negative prognostic marker in HER2-positive breast cancer patients treated (trastuzumab plus chemotherapy) in both the neoadjuvant and adjuvant settings. The gene discussed is ERBB2; the disease is breast carcinoma.